Combination of paclitaxel and carboplatin in neoadjuvant chemotherapy of marginally resectable (IIIA) non-small cell lung cancer - Followed by selective adjuvant chemotherapy;Kombinace paklitaxel a karboplatina v neoadjuvantní chemoterapii u hraničně operabilních stádií IIIA nemalobuněčného karcinomu plic. Následná cílená pooperační adjuvantní chemoterapie

Studia Pneumologica et Phthiseologica

Volumn 62, Issue 1, 2002, Pages 19-23

  Kolek, Vitězslav ^a   Grygarkova I ^a   Hajduch M ^a   Chmelarova A ^a   Trojanec, R ^a   Klein, J ^a   Neoral, C ^a   Kral V ^a   Mihal V ^a  

^a NONE   (Czech Republic)

Author keywords

In vitro chemoresistance; Neoadjuvant chemotherapy; Non small cell lung cancer; Operability; Selective adjuvant chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; TUMOR CELL;

EID: 0036248498     PISSN: 03712222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Long-term survival after concurrent Cisplatin/Etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky stages IIIA (N2) and IIIB non-small cell lung cancer (NSCLC): 6-Year outcomes from Southwest Oncology Group Study 8805
2. Randomized phase III trial comparing cisplatin/etoposid versus carboplatin/paclitaxel in advanced and Metastatic non-small-cell-lung cancer (NSCLC)
3. Phase III trial of neo-adjuvant chemotherapy (NCT) in resectable stage I. (except TINO), II, IIIa non-small cell lung cancer (NSCLC): The French experience
4. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small-cell lung cancer. Preliminary results comparing seguential phase II trials
5. Invasive and noninvasive techniques of staging potentially operable lung cancer
6. Decreased in-vitro chemosensitivity of tumour cells in patients suffering from mallignant diseases with a poor prognosis
7. Combined treatment modalities in non-small cell lung cancer: A French experience
8. A feasibility study of neoadjuvant vinorelbine adn cisplatinum for patients with early stage, resectable non small cell lung cancer (NSCLC)
9. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer. A phase II toxicity, response and survival analysis
10. Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients
11. Randomized trial of neoadjuvant therapy for lung cancer: Interim analysis
12. Kombinovaná léčba bronchogenniho karcinomu v letech 1990-1998. Zkušenosti s cytostatiky III. Generace
13. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach
14. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer
15. Prognostic impact of mutated K-ras gene in surgicall resected non-small cell lung cancer patients
16. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIa non-small cell lung cancer
17. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiation therapy: A Southwest Oncology Group trial
18. A randomized phase III trial of four chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC)
19. The limits of surgical treatment of non-small cell lung cancer
20. Indukční chemoterapie u nemalobuněčného plicního karcinomu stadia III
21. Randomized trial of chemotherapy (CT) and twice-daily chemoradiation (hfRT/CT) versus chemotherapy (CT) alone before surgery in stage non-small cell lung cancer (NSCLC): Interim analysis of toxicity